Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

30 October 2022

11 Pages

Proton Pump Inhibitors Use and the Risk of Pancreatic Cancer: Evidence from Eleven Epidemiological Studies, Comprising 1.5 Million Individuals

,
,
,
and
1
Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan
2
International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei 110301, Taiwan
3
Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei 110301, Taiwan
4
Alfred-Wegener-Institut Helmholtz-Zentrum für Polar-und Meeresforschung, Am Handelshafen 12, D-27570 Bremerhaven, Germany
This article belongs to the Section Cancer Epidemiology and Prevention

Simple Summary

Proton pump inhibitors are commonly prescribed medications for gastrointestinal disorders, which bring gastric acid down to normal levels. However, the effects of PPI on pancreatic risk remain unclear. Therefore, we conducted a systematic review and meta-analysis to investigate the association between PPI use and pancreatic cancer. The overall combined estimate suggested that PPI therapy was significantly associated with an increased risk of pancreatic cancer (RRadj. 1.63, 95%CI: 1.19–2.22, p = 0.002). However, this effect might be biased due to users’ definitions, exposure periods, and other confounding factors. Large epidemiological studies with controlled bias are therefore warranted to confirm or refute the association found in this study. Considering the possible carcinogenic effect of PPI, physicians should be vigilant when prescribing high-dose or long-term PPI.

Abstract

Previous epidemiological studies have shown that proton pump inhibitor (PPI) may modify the risk of pancreatic cancer. We conducted an updated systematic review and meta-analysis of observational studies assessing the effect of PPI on pancreatic cancer. PubMed, Embase, Scopus, and Web of Science were searched for studies published between 1 January 2000, and 1 May 2022. We only included studies that assessed exposure to PPI, reported pancreatic cancer outcomes, and provided effect sizes (hazard ratio or odds ratio) with 95% confidence intervals (CIs). We calculated an adjusted pooled risk ratio (RR) with 95%CIs using the random-effects model. Eleven studies (eight case–control and three cohorts) that reported 51,629 cases of pancreatic cancer were included. PPI was significantly associated with a 63% increased risk of pancreatic cancer (RRadj. 1.63, 95%CI: 1.19–2.22, p = 0.002). Subgroup analysis showed that the pooled RR for rabeprazole and lansoprazole was 4.08 (95%CI: 0.61–26.92) and 2.25 (95%CI: 0.83–6.07), respectively. Moreover, the risk of pancreatic cancer was established for both the Asian (RRadj. 1.37, 95%CI: 0.98–1.81) and Western populations (RRadj.2.76, 95%CI: 0.79–9.56). The findings of this updated meta-analysis demonstrate that the use of PPI was associated with an increased risk of pancreatic cancer. Future studies are needed to improve the quality of evidence through better verification of PPI status (e.g., patient selection, duration, and dosages), adjusting for possible confounders, and ensuring long-term follow-up.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.